Wall Street RegretsThe regret calculator.

What if you'd held IBB?

A $1,000 investment in iShares Biotechnology ETF (IBB) at the month-end close of 2001-02 would be worth $7,017 at the close of 2026-08 — +601.7% total return, dividends reinvested. The same $1,000 in the S&P 500 would be worth $6,216.

$1,000 since 2001$7,017Total return+601.7%Multiple7.0×CAGR+7.9%

Your scenario

Dates resolve to the nearest month-end close.
Leave empty for "held until today".
Invested at each month-end. Starts on the buy date.

Result

Worth$7,017Gain+$6,017 (+601.7%)Multiple7.0×CAGR+7.9%

    If you'd bought $1,000 at the start of each year

    Value of $1,000 invested on January 1 of each year, held to 2026-08, dividends included.

    2001$7,0172002$7,4692003$13,7752004$9,4492005$9,0172006$8,8022007$8,7452008$8,3672009$9,5372010$8,2812011$7,2102012$6,4532013$4,8842014$2,9512015$2,2052016$1,9762017$2,5152018$2,0772019$2,2962020$1,8312021$1,4532022$1,4392023$1,6672024$1,6072025$1,6472026$1,287

    Every year, $1,000 from 2001

    YearValue of $1,000Year return
    2001$1,000
    2002$542-45.8%
    2003$790+45.8%
    2004$828+4.8%
    2005$849+2.5%
    2006$854+0.6%
    2007$893+4.5%
    2008$783-12.3%
    2009$902+15.2%
    2010$1,036+14.8%
    2011$1,157+11.7%
    2012$1,529+32.1%
    2013$2,531+65.5%
    2014$3,388+33.8%
    2015$3,779+11.6%
    2016$2,970-21.4%
    2017$3,596+21.1%
    2018$3,253-9.5%
    2019$4,080+25.4%
    2020$5,141+26.0%
    2021$5,190+1.0%
    2022$4,479-13.7%
    2023$4,648+3.8%
    2024$4,536-2.4%
    2025$5,804+28.0%
    2026$7,469+28.7%

    Best and worst month-end to buy

    The best single month-end close to have bought IBB was 2002-09 ($14.76): $1,000 then is $14,699 today. The worst was 2026-08 ($217): $1,000 then is $1,000.

    FAQ

    What would $1,000 in IBB be worth today?

    A $1,000 investment in iShares Biotechnology ETF (IBB) at the start of 2001 would be worth about $7,017 today, a total return of +601.7%. Dividends are reinvested in these figures.

    What were the best and worst years for IBB?

    iShares Biotechnology ETF (IBB)'s strongest calendar year since 2001 was 2013, a +65.5% return — $1,000 held through that year became about $1,655 by year-end. Its weakest year was 2002, at -45.8%.

    Does the calculator include dividends and splits?

    Yes where available. Prices are adjusted for both stock splits and reinvested dividends (total return), the same measure brokerages use.

    How much would $100 per month in IBB have grown?

    Investing $100 at the end of every month since 2001-02 would have grown to about $157,634 on $30,700 invested.

    Did IBB beat the S&P 500?

    Over the same period, $1,000 in the S&P 500 index would be worth $6,216. IBB beat the S&P 500 by +12.9% in total return.

    Is this investment advice?

    No. Wall Street Regrets is an entertainment and education tool. Every number is a historical calculation, not a prediction, and past performance never guarantees future results.

    Methodology

    iShares Biotechnology ETF (IBB) historical total-return data from 2001-02 to 2026-08, reduced to month-end closes for the tables above.

    Returns use adjusted close prices from Yahoo Finance historical data — adjusted for stock splits and reinvested dividends — the same convention used by major brokerages. A "year" scenario invests $1,000 at the prior December's month-end close and values it at the latest available month-end close. Non-USD amounts are converted at historical month-end exchange rates (Yahoo Finance): to USD on the buy date and back to your currency at the latest rate, so the return reflects the currency move as well as the asset.

    Month-end resolution means intra-month extremes are not captured in tables; the calculator uses exact trading-day closes where daily data is available. Figures ignore taxes, fees, and the currency effects of non-USD listings. History is not a forecast. Wall Street Regrets is entertainment, not investment advice.

    Full methodology →

    What if you'd held…

    Data: adjusted close prices via Yahoo Finance. As of 2026-08. Not financial advice.